Katharine M. Esselen, MD, MBA

Articles by Katharine M. Esselen, MD, MBA

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Katharine M. Esselen, MD, MBA, attending gynecologic oncologist, Beth Israel Deaconess Medical Center, assistant professor of obstetrics, gynecology, and reproductive biology, Harvard Medical School

The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA

ByUrsula A. Matulonis, MD,Katharine M. Esselen, MD, MBA

March 31st 2026

Drs Matulonis and Esselen explore the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes.

Katharine M. Esselen, MD, MBA

Articles by Katharine M. Esselen, MD, MBA

The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg